Results 81 to 90 of about 2,934,766 (329)

Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer

Cell Death and Disease
PARP inhibitors and HDAC inhibitors have been approved for the clinical treatment of malignancies, but acquired resistance of or limited effects on solid tumors with a single agent remain as challenges.
Qingyun Zhu, Qiuzi Dai, Lei Zhao, Chang Zheng, Qinyuan Li, Zigao Yuan, Lulu Li, Zhuoye Xie, Zixuan Qiu, Wenjun Huang, Guowen Liu, Xuyu Zu, Bizhu Chu, Yuyang Jiang   +13 more
doaj   +1 more source

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors

Disease Models & Mechanisms, 2016
Clinical management of abdominal aortic aneurysm (AAA) is currently limited to elective surgical repair because an effective pharmacotherapy is still awaited.
María Galán, Saray Varona, Mar Orriols, José Antonio Rodríguez, Silvia Aguiló, Jaume Dilmé, Mercedes Camacho, José Martínez-González, Cristina Rodriguez   +8 more
doaj   +1 more source

Effects of HDAC inhibitors on neuroblastoma SH-SY5Y cell differentiation into mature neurons via the Wnt signaling pathway

BMC Neuroscience, 2023
Histone deacetylase (HDAC) inhibitors affect cell homeostasis, gene expression, and cell cycle progression and promote cell terminal differentiation or apoptosis.
Jiyun Choi, Jinsu Hwang, Mahesh Ramalingam, Han-Seong Jeong, Sujeong Jang   +4 more
doaj   +1 more source

BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1 [PDF]

, 2013
The bromodomain and extra terminal (BET) family protein bromodomain containing protein 4 (BRD4) is an epigenetic regulator recently identified as a therapeutic target for several hematological cancers, notably mixed lineage leukemia-fusion acute myeloid ...
Bastow, Sarah, Chevassut, Timothy James Telfer, Horne, Gillian Abigail, Stewart, Helen Jayne Susan   +3 more
core   +1 more source

Cinnamic‐Hydroxamic‐Acid Derivatives Exhibit Antibiotic, Anti‐Biofilm, and Supercoiling Relaxation Properties by Targeting Bacterial Nucleoid‐Associated Protein HU

Advanced Science, EarlyView.
Cinnamic‐hydroxamic‐acid derivatives (CHADs) are identified as novel inhibitors of the bacterial nucleoid‐associated protein HU, exhibiting potent antibacterial, anti‐biofilm (both inhibition and eradication), and DNA relaxation (anti‐supercoiling) activities. Moreover, CHADs demonstrate strong synergistic effects with multiple antibiotics.
Huan Chen, Yingqi Xu, Zhaoping Xiong, Hongliang Wang, Xin Wang, Yue Kang, Zhonglin Wang, Xiaoyan Zeng, Yahui Liu, Yehuan Zheng, Wei Chen, Mengzhe Li, Zhenyue Hu, Chi Xu, Yue Wu, Yawen Wang, Zuyi Yuan, Shuai Yuan, Huadong Liu, Steve Matthews, Nan Qiao, Yan Li, Bing Liu   +22 more
wiley   +1 more source

HDAC inhibitors enhance the immunotherapy response of melanoma cells.

OncoTarget, 2017
We focused on the ability of the pan-histone deacetylase (HDAC) inhibitors AR42 and sodium valproate to alter the immunogenicity of melanoma cells. Treatment of melanoma cells with HDAC inhibitors rapidly reduced the expression of multiple HDAC proteins ...
Laurence A Booth, Jane L. Roberts, A. Poklepovic, J. Kirkwood, P. Dent   +4 more
semanticscholar   +2 more sources

Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β‐Thalassemia

Advanced Science, EarlyView.
Context of Research: β‐thalassemia affects millions worldwide. DNMT inhibitors are effective HbF‐inducers that benefit patients with β‐thalassemia. Existing DNMT inhibitors are not approved for β‐thalassemia treatment due to dose‐limiting toxicity.What We Find: DMT207 traps DNMT1 into helix‐kinked inactive conformation and enhances its interaction with
Yijie Shen, Jiale Wei, Shibing Tang, Dongliang Wu, Liangyi Zong, Shuyuan Ma, Qing Xiong, Ruijie Gong, Siyuan Xu, Chuxuan Peng, Qin Feng, Songchen Liu, Qitong Liu, Yuhua Ye, Quan Zhao, Cheng Luo, Peng Huang, Zhihai Li, Xiangqian Kong, Xianjiang Lan   +19 more
wiley   +1 more source

Mutation of the co-chaperone Tsc1 in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity [PDF]

, 2019
The molecular chaperone Heat shock protein 90 (Hsp90) is essential for the folding, stability, and activity of several drivers of oncogenesis. Hsp90 inhibitors are currently under clinical evaluation for cancer treatment, however their efficacy is ...
Backe, Sarah J, Baker-Williams, Alexander J, Bourboulia, Dimitra, Bratslavsky, Gennady, Bratslavsky, Michael S, Hughes, Michael, Jacob, Joseph M, Mollapour, Mehdi, Sager, Rebecca A, Shapiro, Oleg, Wong, Michael, Woodford, Mark R   +11 more
core   +1 more source

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells [PDF]

, 2016
Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine kinase is frequently overexpressed in cancers leading to uncontrolled receptor activation
Bown, James, Deeni, Yusuf Y., Goltsov, Alexey, Harrison, David J., Khalil, Hilal S., Langdon, Simon P., Soininen, Tero   +6 more
core   +3 more sources

The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease

Translational Neurodegeneration, 2017
Alzheimer’s disease (AD) is a chronic neurodegenerative disease, which is associated with learning and memory impairment in the elderly. Recent studies have found that treating AD in the way of chromatin remodeling via histone acetylation is a promising ...
Shuang-shuang Yang, Rui Zhang, Gang Wang, Yong-fang Zhang   +3 more
semanticscholar   +1 more source